NCT04512235 2026-04-07
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
Alexion Pharmaceuticals, Inc.
Chang Gung Memorial Hospital
Chinese PLA General Hospital
H. Lee Moffitt Cancer Center and Research Institute
Medical College of Wisconsin